A new study examines whether adding the immunotherapy drug pembrolizumab to standard treatment for advanced head and neck cancer is worth the cost. Researchers found the value may depend heavily on a patient’s biomarker score, raising a bigger question about who stands to benefit most from the added treatment.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.